RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer

Receptor activator of NF-κB ligand (RANKL) and its receptor RANK, are members of the tumor necrosis factor and receptor superfamilies, respectively. Antibodies targeting RANKL have recently been evaluated in combination with anti-CTLA4 in case reports of human melanoma and mouse models of cancer. Ho...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncoimmunology
Glavni autori: Ahern, Elizabeth, Harjunpää, Heidi, O'Donnell, Jake S., Allen, Stacey, Dougall, William C., Teng, Michele W. L., Smyth, Mark J.
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2018
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5980384/
https://ncbi.nlm.nih.gov/pubmed/29872559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1431088
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items